| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/14/2006 | US6998110 High speed absorption; mixture of aqueous polar solvent, propellant, active material and flavor |
| 02/14/2006 | US6998106 Radioconjugation of internalizing antibodies |
| 02/14/2006 | US6997909 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/14/2006 | CA2394900C Diabetes management system |
| 02/14/2006 | CA2378533C Erythropoietin conjugates with polyethylenglycol |
| 02/14/2006 | CA2336597C Hepatitis c inhibitor peptides |
| 02/14/2006 | CA2269072C Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/14/2006 | CA2248598C Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors |
| 02/14/2006 | CA2169847C Method for the prevention and treatment of bovine mastitis |
| 02/14/2006 | CA1341497C Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| 02/14/2006 | CA1341496C Production of thrombin inhibitors |
| 02/09/2006 | WO2006015385A2 Anti-angiogenic peptides and methods of use thereof |
| 02/09/2006 | WO2006015297A2 Methods of treating type i diabetes by blocking vegf-mediated activity |
| 02/09/2006 | WO2006015275A2 Method for enhancing bone formation |
| 02/09/2006 | WO2006015189A2 Enzymatic inactivation of transmissible spongiform encephalopathy agents and detection thereof |
| 02/09/2006 | WO2006015137A2 A method for managing cholesterol with a serum-free and mitogen free cytokine mixture |
| 02/09/2006 | WO2006015084A2 Compositions, kits and assays containing reagents directed to cortactin and an arg/abl protein kinase |
| 02/09/2006 | WO2006015057A2 C-terminally truncated interferon |
| 02/09/2006 | WO2006015005A2 Use of thyrotropin for regeneration of bone |
| 02/09/2006 | WO2006014839A2 Activated protein c inhibits undesirable effects of plasminogen activator in the brain |
| 02/09/2006 | WO2006014744A2 Compounds that inhibit hsp90 protein-protein interactions with iap proteins |
| 02/09/2006 | WO2006014673A2 Insulin-oligomer conjugates, formulations and uses thereof |
| 02/09/2006 | WO2006014559A2 Cyclic peptides for treatment of cachexia |
| 02/09/2006 | WO2006014552A2 Cyclic peptides for treatment of cachexia |
| 02/09/2006 | WO2006014493A2 Mechanically activated channel blocker |
| 02/09/2006 | WO2006014468A2 Saif, an anti-inflammatory factor, and methods of use thereof |
| 02/09/2006 | WO2006014429A2 Cidofovir peptide conjugates as prodrugs |
| 02/09/2006 | WO2006014218A2 Treatment or prevention of cancer or cardiovascular disease with methenyltetrahydrofolate synthetases |
| 02/09/2006 | WO2006014121A1 Muscular dystonia treatment preparation produced from clostridium botulinum culture toxin and method for the production thereof |
| 02/09/2006 | WO2006013552A2 Articles of peptide nanostructures and method of forming the same |
| 02/09/2006 | WO2006013388A2 Materials and methods for modulating signalling by alpha-v integrin molecules |
| 02/09/2006 | WO2006013336A1 Hpv vaccine comprising peptides from host cell proteins |
| 02/09/2006 | WO2006013334A1 Hai-1 and hai-2 in cancer therapy |
| 02/09/2006 | WO2006013003A1 Use of products derived from selenoprotein t, in its application related to calcium homeostasis |
| 02/09/2006 | WO2005123771A3 Oligomeric peptides and their use for the treatment of hiv infections |
| 02/09/2006 | WO2005113786A3 Diagnostics and therapeutics for diseases associated with chymase (cma1) |
| 02/09/2006 | WO2005112987A3 Method of preparation and use of fibrinolytic enzymes in the treatment of disease |
| 02/09/2006 | WO2005111064A8 Cyclopeptide derivatives with anti-integrin activity |
| 02/09/2006 | WO2005110046A3 Method of enhancing uptake of keratinocyte growth factor |
| 02/09/2006 | WO2005095444A3 Synthetic peptides containing the motif ‘ywwlxp’ as anthrax toxin antidotes |
| 02/09/2006 | WO2005093425A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 58 (gpr58) |
| 02/09/2006 | WO2005093423A3 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara) |
| 02/09/2006 | WO2005089789A3 Y2 selective receptor agonists for therapeutic interventions |
| 02/09/2006 | WO2005086800A3 Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling |
| 02/09/2006 | WO2005068663A3 Methods of using peroxisome proliferator-activated receptor alpha target genes |
| 02/09/2006 | WO2005056054A3 METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB |
| 02/09/2006 | WO2005056041A3 METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ |
| 02/09/2006 | WO2005042027A3 Antagonists of the bradykinin b1 receptor |
| 02/09/2006 | WO2005016953A3 Antagonistic analogs of gh-rh (2003) |
| 02/09/2006 | WO2005010038A3 Peptide protein translation inhibitor and the use thereof for protein translation control |
| 02/09/2006 | WO2004056983A3 Metalloprotease proteins |
| 02/09/2006 | WO2004009616A3 Ghrelin analogs |
| 02/09/2006 | WO2004002415A3 Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| 02/09/2006 | WO2003100027A3 Mutant fibronectin and tumor metastasis |
| 02/09/2006 | WO2003040693A3 Peptides that home to tumor lymphatic vasculature and methods of using same |
| 02/09/2006 | WO2002097110A3 TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF |
| 02/09/2006 | WO2002088316A3 G-protein coupled receptors |
| 02/09/2006 | US20060031962 Antifungal polypeptides |
| 02/09/2006 | US20060031956 Nucleotide sequences for gene regulation and methods of use thereof |
| 02/09/2006 | US20060031951 Improved modalities for the treatment of degenerative diseases of the retina |
| 02/09/2006 | US20060031946 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| 02/09/2006 | US20060030942 calcitonin gene-related peptide, cholecystokinin, dynorphin, enkephalin, galanin, neuropeptide Y, neurotensin, somatostatin, substance P, thyrotropin-releasing hormone, vasoactive intestinal peptide |
| 02/09/2006 | US20060030838 Methods and devices for delivering GLP-1 and uses thereof |
| 02/09/2006 | US20060030695 Platelet-derived growth factor-D; anticarcinogenic agents, angiogenesis inhibition; tissue-targeted therapy; immunoassays; cancer diagnosis |
| 02/09/2006 | US20060030694 Antitumor agents; fusion protien increases biological half life |
| 02/09/2006 | US20060030622 Compounds and methods for the treatment of urogenital disorders |
| 02/09/2006 | US20060030605 Pharmaceutical compounds |
| 02/09/2006 | US20060030594 Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 02/09/2006 | US20060030562 Use of an inhibitor of cathepsin-S-or-B to treat or prevent chronic obstructive pulmonary disease |
| 02/09/2006 | US20060030542 Protecting a muscarinic acetylcholine receptor in patient, by administering at least one pyrophosphates with active drug; prevent tissue damage, increasing the efficacy of a therapeutic agent |
| 02/09/2006 | US20060030534 Alzheimer's, Parkinson's, multiple sclerosis, schizophrenia, epilepsy, depression and pain |
| 02/09/2006 | US20060030533 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents |
| 02/09/2006 | US20060030532 Directly contacting bacteria or fungi, especially Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Proteus vulgaris, Enterococcus faecalis, or Candida albicans, with a substance P analog |
| 02/09/2006 | US20060030531 Pharmaceutical composition comprising factor VII polypeptide and PAI-1 polypeptide |
| 02/09/2006 | US20060030530 Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
| 02/09/2006 | US20060030529 Use of VEGF inhibitors for treatment of eye disorders |
| 02/09/2006 | US20060030528 Compositions and methods for treating peripheral vascular disease |
| 02/09/2006 | US20060030527 Rage fusion proteins and methods of use |
| 02/09/2006 | US20060030526 Stable suspension formulations of erythropoietin receptor agonists |
| 02/09/2006 | US20060030525 Apolipoprotein A-I derivatives with altered immunogenicity |
| 02/09/2006 | US20060030524 Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| 02/09/2006 | US20060030523 Binding to LRP5 or LRP6 receptor; promoting growth with DAN family bone morphogenetic protein antagonist |
| 02/09/2006 | US20060030522 ALK7 and myostatin inhibitors and uses thereof |
| 02/09/2006 | US20060030521 Remodeling and glycoconjugation of peptides |
| 02/09/2006 | US20060030520 GDF3 propeptides and related methods |
| 02/09/2006 | US20060030519 Composition for reducing blood lipids |
| 02/09/2006 | US20060030518 Acylated insulin |
| 02/09/2006 | US20060030517 Anti-cancer agent |
| 02/09/2006 | US20060030045 Antisense modulation of c/ebp beta expression |
| 02/09/2006 | US20060030019 HDAC9 polypeptides and polynucleotides and uses thereof |
| 02/09/2006 | US20060030005 C3b/C4b complement receptor-like molecules and uses thereof |
| 02/09/2006 | US20060030004 Solid phase synthesis |
| 02/09/2006 | US20060030001 Useful polypeptides |
| 02/09/2006 | US20060029998 Codes with nucleic acids; antiinflammatory agents; immunomodulation |
| 02/09/2006 | US20060029990 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
| 02/09/2006 | US20060029944 Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells |
| 02/09/2006 | US20060029932 Method for preventing HIV-1 infection of CD4+ cells |
| 02/09/2006 | US20060029931 Small, interfering RNA (siRNA) molecules which inhibit expression of HALP (HIV-Associated Life Preserver) protein cloned into a plasmid or retroviral vector for introduction into host cells; screening HIV-modulating componds which prevent apoptosis resistance of infected cell; gene therapy |
| 02/09/2006 | US20060029928 Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (prrsv), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a prrsv and a method of detecting a |
| 02/09/2006 | US20060029678 Process for the production of implants |